<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078779</url>
  </required_header>
  <id_info>
    <org_study_id>E/09/482</org_study_id>
    <nct_id>NCT01078779</nct_id>
  </id_info>
  <brief_title>The Chloroquine for Influenza Prevention Trial</brief_title>
  <acronym>CHIP</acronym>
  <official_title>A Randomised, Double-blind, Placebo Controlled Trial of Chloroquine for the Prevention of Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled trial to determine the efficacy of chloroquine for the prevention of
      influenza
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory-confirmed influenza-like illness</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serologically-confirmed influenza infection (symptomatic or asymptomatic)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Four-fold rise in influenza antibody titre at week 12 compared to the baseline sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1516</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <other_name>Chloroquine phosphate</other_name>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 -65

          -  Have the ability to provide informed consent

          -  If a woman of child-bearing potential, willing to use contraception for the period of
             the trial

        Exclusion Criteria:

          -  Acute influenza-like illness at screening

          -  History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy
             of any cause, cardiac arrhythmias, or serious hepatic or renal disease

          -  Pregnancy or breast feeding

          -  Current use of medication with known serious hepatotoxic effects

          -  Current use of medication with known serious interaction with CQ: amiodarone,
             anticonvulsants, ciclosporin, digoxin, mefloquine, moxifloxacin

          -  Current severe depression (as indicated by current use of antidepressant medication)

          -  Known serious retinal disease

          -  Current or recent (within the past 30 days) participation in any other clinical
             intervention trial.

          -  Known G6PD deficiency

          -  Vaccination for influenza (seasonal or H1N1 strain) within the 3 months prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas I Paton, MD FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Lee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Medicines Unit, National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>February 28, 2010</last_update_submitted>
  <last_update_submitted_qc>February 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Nicholas Paton</name_title>
    <organization>National University of Singapore</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Prevention</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Randomised controlled trial</keyword>
  <keyword>Respiratory virus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

